[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360; 361-380; 401-420; 421-440; 441-460


NICE TAs 381-400






DHFT Formulary link


East Midlands Cancer Network link (cancer drugs only)

TA 381

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotheraphy


TA 382

Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)



Not recommended       


TA 383

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis


10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout

TA 384

Nivolumab for treating advanced (unresectable or metastatic) melanoma


TA 385

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

2.12 Lipid lowering drugs


TA 386

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis


TA 387

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated


TA 388

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction      

2.5 Antihypertensive therapy 

TA 389

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer                


TA 390

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes 

6.1.1 - Insulin, oral antidiabetic drugs, biguanides          

TA 391

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel 


TA 392

Adalimumab for treating moderate to severe hidradenitis suppurativa

13.5.3 Drugs affecting the immune response

TA 393 

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

2.12 Lipid lowering drugs

TA 394

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

2.12 Lipid lowering drugs

TA 395 

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small cell lung cancer


TA 396

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma 


TA 397

Belimumab for treating active autoantibody-positive systemic lupus erythematosus

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout         

TA 398

Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation      

Not recommended by NICE

TA 399

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts 


Not recommended by NICE

TA 400

Nivolumab in combination with ipilimumab for treating advanced melanoma